NVCR News and Press, NovoCure Limited From 04/13/21

Gainers: Mackinac Financial (MFNC) +56%.NovoCure (NVCR) +42%.vTv Therapeutics (VTVT) +42%.Digimarc (DMRC) +20%.PLBY Group (PLBY) +20%.Ballantyne Strong (BTN) +20%.Birks Group (BGI) +18%.Zai Lab (ZLAB) +16%.B. Riley Financial (RILY) +15%.Nam Tai Property (NTP) +14%.Losers: Brook...

After reviewing interim results from 210 patients participating in a phase 3 study, an independent monitoring committee is recommending changes to Novocure 's (NASDAQ: NVCR) non-small cell lung cancer (NSCLC) trial. Specifically, the committee is suggesting that the number of patien...

Gainers: NovoCure (NVCR) +45%, vTv Therapeutics (VTVT) +28%, Rigel Pharmaceuticals (RIGL) +15%, Zai Lab (ZLAB) +14%, Vallon Pharmaceuticals (VLON) +10%.Losers: Avenue Therapeutics (ATXI) -17%, AdaptHealth (AHCO) -17%, Brook...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of oncology firm Novocure (NASDAQ: NVCR ) stock are soaring to start the day on Tuesday following a promising update from its phase 3 tumor-treating trial . Source: CI Photos / Shutterstock.com An inde...

NovoCure Limited (NVCR) +62% after DMC recommends shorter phase 3 NSCLC trial.Mackinac Financial Corporation (MFNC) +31% on merger agreement with Nicolet Bankshares.Dragon Victory International Limited (LYL) +44%.Optibase (OBAS) +20%.Tian Ruixiang Holdings Ltd (TIRX) +26%.vTv Therap...

Novocure (NVCR) shares are up more than 81% in premarket trading after a data monitoring committee (DMC) recommended a reduced trial duration and patient numbers in its phase 3 trial for its Tumor Trial Fields (TTF) treatment for non-small cell lung cancer.The DMC told Novocure that...

Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial SHANGHAI and SAN FRAN...

Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial Novocure (NASDA...

Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10 to April 15, 2021. Research spanning seven s...

NovoCure invented a new type of cancer treatment based on TTF (tumor treating fields). They use electricity to disrupt the division of cancer cells. The company is working to expand use cases via FDA approval, which could drive growth for years to come. The stock isn't "cheap" but...